|Over a week ago|
Praxis Precision Medicines appoints Tim Kelly as Chief Financial Officer » 08:0605/2505/25/21
Praxis Precision Medicines announced the appointment of Tim Kelly as chief financial officer, effective immediately. Kelly joins Praxis from Foundation Medicine, where he served as chief financial officer and head of corporate management. Kelly brings more than 20 years of experience in the life sciences, pharmaceutical and biotechnology industries.
|Over a month ago|
Oppenheimer to hold a virtual summit » 09:3805/2105/21/21
BMRN, CATB, CERC, CLRB, CMMB, CRBP, DCTH, ELOX, MGTX, MITO, PRAX, SBBP, SLNO, SVRA, TARA
Rare & Orphan Disease…
Rare & Orphan Disease Virtual Summit to be held on May 21.
Praxis Precision Medicines 5M share Secondary priced at $18.25 » 06:0905/1405/14/21
The deal size was…
The deal size was increased to 5M shares from 4M shares. BofA, Cowen, Piper Sandler and Wedbush acted as joint book running managers for the offering.
Praxis Precision Medicines announces 4M share common stock offering » 16:2405/1105/11/21
Praxis Precision Medicines announced that it has commenced an underwritten public offering of 4M shares of its common stock. Praxis intends to use the net proceeds from the offering, together with its existing cash, cash equivalents and short-term investments, to (i) advance PRAX-114 into and through the completion of the Phase 2/3 Aria Study in monotherapy major depressive disorder, which is intended to satisfy one of two registrational trials required by the FDA to support clinical efficacy for monotherapy MDD, advance PRAX-114 into and through the completion of Praxis' Phase 2 trial for the adjunctive treatment of MDD, complete Part B of the Phase 2a clinical trial for PRAX-114, initiate a Phase 3 monotherapy trial in MDD, initiate and complete a Phase 2 trial in PTSD, initiate and complete a Phase 2 trial in essential tremor and pursue the development of PRAX-114 in an additional indication; (ii) complete its ongoing Phase 2a clinical trial and a Phase 2 randomized, controlled clinical trial for PRAX-944 in ET and initiate and complete a Phase 2 trial of PRAX-944 in Parkinson's Disease; (iii) complete its ongoing PRAX-562 Phase 1 healthy volunteer trial and initiate and complete Phase 2 trials of PRAX-562 in Short-lasting Unilateral Neuralgiform headache attacks with Conjunctival injection and Tearing, Short-lasting Unilateral Neuralgiform headache with Autonomic symptoms, and Trigeminal Neuralgia, and in developmental epileptic encephalopathies, including SCN8A-DEE and SCN2A-DEE and (iv) advance other programs in its pipeline and support working capital and other general corporate purposes.BofA Securities, Cowen and Piper Sandler are acting as joint bookrunning managers for the offering, and Wedbush PacGrow is acting as lead manager for the offering.
Praxis Precision Medicines files to sell 4M shares of common stock 16:1905/1105/11/21
Praxis Precision Medicines expects cash to fund operations into 4Q22 » 08:0705/1105/11/21
As of March 31, 2021,…
As of March 31, 2021, Praxis had $270.8 million in cash, cash equivalents and marketable securities, compared to $296.6 million in cash and cash equivalents as of December 31, 2020. This decrease of $25.8 million primarily reflects cash used in operations. The company's cash, cash equivalents and marketable securities as of March 31, 2021 are expected to fund operations into the fourth quarter of 2022.
Praxis Precision Medicines reports Q1 EPS (71c), consensus (74c) » 08:0705/1105/11/21
"I'm inspired by our team's continued execution and the progress throughout our pipeline during the first quarter, with key milestones achieved across each of our programs. As the pipeline advances, our conviction in our programs continues to grow," said Marcio Souza, president and chief executive officer of Praxis. "In addition to the ongoing enrollment in our PRAX-114 Phase 2/3 Aria study for monotherapy MDD, we are excited to announce the expansion of PRAX-114 into post-traumatic stress disorder and essential tremor, as well as the expansion of PRAX-944 into Parkinson's disease. These disorders all have significant unmet need, as well as both genetic and mechanistic linkage to the respective targets and programs. We believe that Praxis' foundational approach to identifying targets through human genetics, the extensive use of translational tools to inform development and always keeping patient needs top of mind have been instrumental in developing a deep pipeline of CNS programs with considerable optionality."
Praxis Precision Medicines receives orphan drug designation for PRAX-562 » 09:0204/3004/30/21
Praxis Precision Medicines announced that the Food and Drug Administration has granted orphan drug designation to PRAX-562 for the treatment of SCN2A development and epileptic encephalopathy. PRAX-562 is a small molecule and is the first selective persistent sodium current blocker in development for the treatment of a wide range of rare CNS disorders. Praxis plans to initiate a Phase 2 clinical trial in the first half of 2022 to explore the potential for PRAX-562 to treat a range of rare pediatric DEEs, including SCN2A-DEE and SCN8A-DEE. PRAX-562 is currently being evaluated in a Phase 1 clinical trial in adult healthy volunteers.
Praxis Precision Medicines appoints Merit Cudkowicz to board of directors » 08:2004/2904/29/21
Praxis Precision Medicines announced the appointment of Merit Cudkowicz, M.D., to its board of directors. Cudkowicz is the chief of neurology at Mass General Hospital, director of the Sean M. Healey & AMG Center for ALS, and director and the Julieanne Dorn professor of neurology at Harvard Medical School.
Praxis Precision Medicines gets FDA designation in SCN2A Encephalopathy » 06:3104/2804/28/21
Praxis Precision Medicines received orphan drug designation from the FDA for the treatment of SCN2A Developmental and Epileptic Encephalopathy. Reference Link